| Request a sample from "The Infoshop", another service of Global Information.
|
SUMMARY
This chapter of New Drug Futures evaluates, compares and contrasts the
prospects for the compounds that will revolutionise the pharmaceutical
industry over the next 5 years and beyond in the cancer sector. The report
includes unique sales forecasts by major product.
The full 400-page report, evaluates, compares and contrasts the prospects for
the compounds that will revolutionise the pharmaceutical industry over the
next 5 years and beyond. The report covers 8 key therapy areas
(alimentary/metabolic, anti-infectives, cancer, cardiovascular, CNS,
musculoskeletal, respiratory, vaccines) and includes unique sales forecasts by
major product. Click here for more information. This chapter is available
separately.
In 2005, we estimate the global anticancer market was worth over US$42 billion
(+12.6% YoY) accounting for 7% of global pharmaceutical sales (US$600
billion). Global sales included the sale of cytotoxics, innovative therapies,
anti-hormonals plus supportive care (such as anti-emetics). This final segment
accounted for nearly half of global sales.
By 2010, the global cancer market is expected to generate sales in excess of
US$60 billion due to growth in the sales of existing innovative products and
the launch of nearly 60 new products which will account for around 30% of
total drug launches. These will offset the decline in sales of cytotoxics and
anti-hormonals, which face generic sales erosion, and the uptake of newer
products in preference to these older agents.
Cancer is the second most common cause of mortality in the developed world and
accounts for around 12.5% of all deaths worldwide. By 2020, it is predicted
that the number of new cases of cancer diagnosed will rise to 16 million per
annum from 11 million in 2002, with cancer-related deaths reaching 10 million
each year versus 6.7 million in 2002. Excluding non-melanoma skin cancers,
lung cancer is the most common cancer worldwide with breast cancer being the
second most prevalent.
There are several new products that, over the next five years, will change the
dynamics within the cancer market. These include, among others:
TABLE OF CONTENTS
CURRENT MARKET SIZE
ADDRESSABLE PATIENT POPULATION
CURRENT TREATMENTS
- SURGERY
- RADIATION
- CHEMOTHERAPY
- NOVEL THERAPIES/MONOCLONAL ANTIBODIES
- HORMONAL THERAPIES
CANCER SALES DRIVERS
CANCER SALES BREAKERS
FUTURE TREATMENTS
MARKET DYNAMICS - WINNERS & LOSERS
KEY DRUG LAUNCHES BY 2010
KEY EVALUATION CRITERIA
KEY CANCER DRUG LAUNCHES BY 2010
- Acapodene (GTx)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor Ratio Analysis
- AP23573 (ARIAD Pharmaceuticals)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor Ratio Analysis
- Dasatinib (Bristol-Myers Squibb)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor Ratio Analysis
- Ixabepilone (Bristol-Myers Squibb)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor Ratio Analysis
- Lapatinib (GlaxoSmithKline)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor Ratio Analysis
- Nexavar (Onyx Pharmaceuticals/Bayer)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor Ratio Analysis
- Panitumumab(Amgen/Abgenix)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor Ratio Analysis
- Revlimid (Celgene)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor Ratio Analysis
- Satraplatin(GPC Biotech/Spectrum Pharmaceutical)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor Ratio Analysis
- Sutent (Pfizer)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor Ratio Analysis
- Telcyta (Telik)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Mangement/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor Ratio Analysis
- Ticilimumab (Pfizer/Amgen)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor Ratio Analysis
- Vatalanib (Novartis/Schering)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor Ratio Analysis
COMPETITOR RATIO ANALYSIS SUMMARY
COMPETITOR RATIO ANALYSIS - COMPANIES
|
